Growth Factors and Diabetic Complications

Diabetic Medicine

Volumn 7, Issue 5, 1990, Pages 387-399

  Flyvbjerg, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetic angiopathy; Growth factors; Growth hormone; Insulin like growth factors; Renal hypertrophy; Somatostatin

Indexed keywords

GROWTH FACTOR; GROWTH HORMONE; SOMATOMEDIN; SOMATOSTATIN;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; KIDNEY HYPERTROPHY; PRIORITY JOURNAL; REVIEW;

DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; GROWTH HORMONE; GROWTH SUBSTANCES; HUMAN; SOMATOMEDINS;

EID: 0025339120     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.1990.tb01413.x     Document Type: Review

References (165)

1. Permanent diabetes produced by pituitary (anterior lobe) injections
2. The production of permanent diabetes by highly purified growth hormone
3. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics
4. Diurnal pattern of blood glucose, serum FFA, insulin, glucagon and growth hormone in normals and juvenile diabetics
5. Diabetes, diabetic angiopathy and growth hormone (hypothesis)
6. The growth hormone dependent sulphation factor in serum from patients with various types of diabetes
7. Importance of raised growth hormone levels in mediating the metabolic derangement of diabetes
8. The effect of growth hormone on glucose metabolism and insulin secretion in man
9. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin
10. Demonstration of the dawn phenomenon in normal human volunteers
11. The ‘dawn phenomenon’—a common occurrence in both non‐insulin‐dependent and insulin‐dependent diabetes mellitus
12. Diabetic regulation and its relationship to microangiopathy
13. Relation of diabetic control to development of microvascular complications
14. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease
15. Hypophysectomy in man: Further experience in severe diabetes mellitus
16. Hypophysectomy for diabetic angiopathy. A controlled clinical trial
17. Pituitary ablation for diabetic retinopathy
18. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation
19. Growth hormone response to thyrotropin‐releasing hormone in diabetes
20. Long‐term follow‐up of patients who underwent yttrium‐90 pituitary implantation for treatment of proliferative diabetic retinopathy
21. Increased skin capillary resistance after hypophysectomy in long term diabetes
22. Quantitative measurements of skin capillary resistance in hypophysectomized long‐term diabetics
23. Growth hormone antiserum suppresses the growth effect of diabetic serum: studies on rabbit aortic medial cell cultures
24. Arterial procollagen type I, type III and fibronectin. Effects of diabetic serum, glucose, insulin, ketone and growth hormone studied on rabbit aortic myomedial cell cultures
25. Diabetes‐like alterations in hemostatic parameters after growth hormone administration for one week in normal man
26. Impact of human growth hormone on plasma lipoprotein concentrations
27. Kidney function and size in insulin dependent diabetics before and during growth hormone administration for one week
28. Predicting diabetic nephropathy in insulin‐dependent patients
29. Increased myocardial contractility following growth hormone administration in normal man
30. Increased myocardial contractility in short‐term type 1 diabetic patients. An echocardiographic study
31. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus
32. Suppression of growth hormone and somatomedin C by longacting somatostatin analogue SMS 201–995 in type 1 diabetes mellitus
33. The effects of SMS 201–995 (Sandostatin) on metabolic profiles in insulin‐dependent diabetes mellitus
34. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin‐dependent diabetes mellitus
35. Somatostatin analogue SMS 201–995 and insulin needs in insulin‐dependent diabetic patients studied by means of an artificial pancreas
36. Metabolic effects of long‐acting somatostatin analogue (Sandostatin) in type 1 diabetic patients on conventional therapy
37. Dawn phenomenon: Suppression by single nightly dose of somatostatin analogue SMS 201–995 (Abstract)
38. Effects of a single nocturnal administration of a long‐acting somatostatin analogue, SMS 201–995 on blood glucose profile during the night, human growth hormone and cortisol secretion in Type 1 diabetic patients (Abstract)
39. Diabetic retinopathy
40. 24‐hour studies of the effect of somatostatin on the levels of plasma growth hormone and glucose in normal subjects and juvenile diabetics
41. Continuous subcutaneous octreotide infusion markedly suppresses IGF‐1 levels whilst only partially suppressing GH secretion in diabetics with retinopathy
42. Somatostatin analogue: an inhibitor of angiogenesis?
43. Effect of SMS 201–995 in rapidly progressive diabetic retinopathy
44. The effect of growth hormone suppression on established preproliferative diabetic retinopathy (Abstract)
45. Renal response to intravenous somatostatin in insulin‐dependent diabetic patients and normal subjects
46. Renal response to a somatostatin analogue (SMS 201–995) in Type 1 (insulin‐dependent) diabetic patients without overt nephropathy (Abstract)
47. Acute effects of the somatostatin analogue SMS 201–995 on kidney function in Type 1 diabetes (Abstract)
48. Preliminary results as regards the evolution of microalbuminuria in diabetic patients treated with Sandostatin® (Abstract)
49. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats
50. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep‐related growth hormone release in young patients with insulin‐dependent diabetes mellitus
51. Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes
52. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin‐dependent diabetes mellitus
53. Early‐morning hyperglycemia in IDDM: Acute effects of cholinergic blockade
54. Somatomedin: proposed designation for sulphation factor
55. Insulin‐infusion‐pump treatment of diabetes
56. Somatomedin C mediates growth hormone negative feed‐back by effects on both the hypothalamus and the pituitary
57. Hormone de croissance, facteurs de croissance et diabete sucre
58. Normalization of growth hormone hyper‐response to exercise in juvenile diabetic after ‘normalization’ of blood sugar
59. Von Willebrand factor (VIII R: Ag), fibronectin, and insulin‐like growth factors I and II in diabetic retinopathy and nephropathy
60. Effect of glycaemic control on serum insulin‐like growth factors in diabetes mellitus
61. Relationships between growth factors (somatomedin C and growth hormone) and body development, metabolic control, and retinal changes in children and adolescents with IDDM
62. Effect of pubertal stage and recent blood glucose control on plasma somatomedin C in children with insulin‐dependent diabetes mellitus
63. Impaired somatomedin generation test in children with insulin‐dependent diabetes mellitus
64. Growth hormone and somatomedin in insulin‐dependent diabetes mellitus
65. Somatomedin in insulin‐dependent diabetes mellitus
66. Plasma somatomedin activity and diabetic retinopathy
67. Insulin‐like growth factors: Studies in diabetics with and without retinopathy
68. Insulin‐like growth factors and diabetic retinopathy (Letter)
69. Somatomedin‐C and diabetic retinopathy
70. The Steno Study Group. Two years experience with continuous subcutaneous insulin infusion in relation to retinopathy and nephropathy
71. Diabetic control and microvascular complications: the near normoglycaemic experience
72. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A Preliminary Multicenter Trial
73. Progression of diabetic retinopathy and changes in serum insulin‐like growth factor I (IGFI) during continuous subcutaneous insulin infusion (CSII)
74. A two‐year follow‐up study of serum insulin‐like growth factor‐I in diabetics with retinopathy
75. Diurnal rhythm of growth hormone‐independent binding protein for insulin‐like growth factors in human plasma
76. Radioimmunoassay of growth hormone‐dependent insulin‐like growth factor binding protein in human plasma
77. Insulin regulates the serum levels of low molecular weight insulin‐like growth factor‐binding protein
78. Dose‐response characteristics for suppression of low molecular weight plasma insulin‐like growth factor‐binding protein by insulin
79. Radioimmunoassay of a 26 000 dalton plasma insulin‐like growth factor binding protein: Control by nutritional variables
80. Isolation of a somatomedin binding protein from preterm human amniotic fluid: development of a radioimmunoassay
81. Transient expression of insulin‐like growth factor I immunoreactivity by vascular cells during angiogenesis
82. Stimulation of endothelial cell growth by sera from diabetic patients with retinopathy
83. Receptors and growth‐promoting effects of insulin and insulin‐like growth factors on cells from bovine retinal capillaries and aorta
84. Insulin‐like growth factor modulates endothelial chemotaxis
85. Insulin‐like growth factors in vitreous: Studies in control and diabetic subjects with neovascularization
86. The role of somatomedin binding protein
87. Glomerular filtration rate and renal plasma flow in acromegaly
88. Renal function following hypophysectomy in man
89. Renal function and kidney size following hypophysectomy in man
90. Some effects of human growth hormone on renal hemodynamics and on tubular phosphate transport in man
91. Kidney function and size in normal subjects before and during growth hormone administration for one week
92. Kidney functions in normal man during short‐term growth hormone infusion
93. The delayed effect of growth hormone on renal function in humans
94. Functional and morphological renal manifestations in diabetes mellitus
95. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy
96. Insulin‐like growth factor I increases glomerular filtration rate and renal plasma flow in man
97. Effects of recombinant IGF‐I on insulin secretion and renal function in normal human subjects
98. Evidence that insulin‐like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats
99. Biosynthetic somatomedin C (SM‐C/IGF I) increases the length and weight of snell dwarf mice
100. Recombinant human insulin‐like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats
101. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor‐1
102. Histopathology associated with elevated levels of growth hormone and insulin‐like growth factor I in transgenic mice
103. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats
104. 3H‐thymidine uptake in diabetic and uninephrectomized rats
105. Kidney tissue insulin‐like growth factor I and initial renal growth in diabetic rats: relation to severity of diabetes
106. Kidney tissue somatomedin C/insulin‐like growth factor 1 and initial renal enlargement in uninephrectomised‐diabetic rats (Abstract)
107. Diabetes‐associated renal growth is decreased in prepubertal rats: the role of insulin‐like growth factor 1 (Abstract)
108. Distinct receptors for insulin‐like growth factor I in rat renal glomeruli and tubules
109. Insulin and insulin‐like growth factor I binding to cultured rat glomerular mesangial cells
110. Receptors for and effects of insulin and IGF‐I in rat glomerular mesangial cells
111. Regulation of insulin‐like growth factor I gene expression by growth hormone
112. Tissue distribution of insulin‐like growth factor I and II ribonucleic acid in the adult rat
113. Relative increase in insulin‐like growth factor I messenger ribonucleic acid level in compensatory renal hypertrophy
114. Regulation of insulin‐like growth factor‐I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues
115. Coordinate decrease of tissue insulinlike growth factor I posttranscriptional alternative mRNA transcripts in diabetes mellitus
116. Glomerular hemodynamics in experimental diabetes mellitus
117. Renal hypertrophy in experimental diabetes mellitus
118. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes
119. Combinations of polytoxin or 12‐0‐tetradecanoylphorbol‐13‐acetate and recombinant human insulin growth‐like factor I or insulin synergistically stimulate prostaglandin production in cultured rat liver cells and squirrel monkey aorta smooth muscle cells
120. Insulin‐like growth factor I stimulates renal epithelial Na+ transport
121. The tubulo glomerular feedback mechanism: functional and biochemical aspects
122. The effect of streptozotocin induced diabetes mellitus on urinary excretion of sodium and renal Na+‐K+‐ATPase activity
123. The mode of development of the retinal vessels and some observations on its significance in certain retinal diseases
124. Endothelial cell mitogens derived from retina and hypothalamus: Biochemical and biological similarities
125. Retina and eye derived endothelial cell growth factors: partial molecular characterisation and identity with acidic and basic fibroblast growth factor
126. Effect of retina derived basic and acidic fibroblast growth factor and lipoproteins on the proliferation of retina derived capillary endothelial cells
127. Induction of DNA synthesis in BALB/C3T3 cells by serum components re‐evaluation of the commitment process
128. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
129. Measurements of basic fibroblast growth factor in bovine retinal endothelial cell conditioned medium (Abstract)
130. Human tumour cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor
131. Fibroblastic growth factors are present in the extracellular matrix produced by endothelial cell in vitro: implications for a role of heparinase‐like enzymes in the neovascular response
132. Atherosclerosis: A problem of the biology of arterial wall cells and their interactions with blood components
133. Atherosclerosis and the arterial smooth muscle cell
134. Cellular transformation by coordinated action of three peptide growth factors from human platelets
135. The effect of platelet‐derived growth factor in cultured microvessel endothelial cells
136. Production of PDGF‐like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury
137. Cultured endothelial cells produce a platelet‐derived growth factor‐like protein
138. Vasoconstriction: a new activity for platelet‐derived growth factor
139. Human platelet‐derived growth factor stimulates prostaglandin synthesis by activation and by rapid de novo synthesis of cyclooxygenase
140. Biosynthesis and regulation of type V collagen in diploid human fibroblasts
141. Abnormalities of platelet‐derived growth factors in insulin‐dependent diabetes
142. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal
143. Isolation and structure of urogastrone and its relationship to epidermal growth factor
144. Factors involved in the modulation of cell proliferation in vivo and in vitro: The role of the fibroblast and epidermal growth factors in the proliferative response of the mammalial cells
145. Immunocytochemical localization of epidermal growth factor in mouse kidney
146. Immunohistochemical localization of epidermal growth factor in rat and man
147. Mouse prepro‐epidermal growth factor synthesis by the kidney and other tissues
148. Renal origin of rat urinary epidermal growth factor
149. EGF binds to specific EGF receptors and stimulates mitogenesis in renal medullary interstitial cells (Abstract)
150. Cellular localization of human epidermal growth factor receptor
151. In vivo cardiovascular, renal and endocrine effects of epidermal growth factor in sheep
152. Serum and epidermal growth factor transiently depolarize quiescent BSC‐1 epithelial cells
153. Epidermal growth factor rapidly activates the hexose monophosphate shunt in kidney cells
154. Effect of epidermal growth factor on sodium transport in the cortical collecting tubules
155. Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy
156. Urinary excretion of human epidermal growth factor in the various stages of diabetic nephropathy
157. Subnormal concentrations of urinary epidermal growth factor in patients with kidney disease
158. Renal EGF after unilateral nephrectomy (Abstract)
159. Epidermal growth factor is expressed by cells in the distal tubulus during postnephrectomy renal growth
160. Role of epidermal growth factor (EGF) in compensatory renal hypertrophy in mice (Abstract)
161. Sera from type 2 diabetic and healthy subjects contain different amounts of a very low molecular weight growth peptide for vascular cells
162. Vascular growth factors and the development of macrovascular disease in diabetes mellitus
163. Increased growth stimulation of fibroblasts from diabetics by diabetes serum factors of low molecular weight
164. Regulation of diabetic serum growth factors for human vascular cells by the metabolic control of diabetes mellitus
165. Diabetic growth peptides of very low molecular weight for human vascular cells in serum from type 2 (non‐insulin‐dependent) diabetic patients